- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02933307
Continuous Monitoring on the General Ward
Continuous Monitoring of Vital Signs in Hospitalized Patients
Rationale: Monitoring patients' vital signs is done to detect clinical deterioration. For this, the MEWS, a scoring list comprising seven vital signs measured by nursing staff, is used. Although the MEWS provides relevant data on patients' health status, the interval measurements may not capture early deterioration of vital signs, especially during the night. As a result, unsafe situations may occur such as periods of low oxygen saturation and cardiac arrhythmias, which are known to complicate postoperative course. Besides, this way of measuring vital signs may be stressful for patients and disturbs patients' sleep. New technology such as ViSi Mobile and HealthPatch allows for remote continuous monitoring of vital signs using wearable devices transmitting relevant data to nurses and clinicians. With this, the investigators think that clinical deterioration may be detected in an early phase and reduce nurse work load and patient distress.
Objective: to investigate the feasibility of wearable devices on the general ward.
Study design: feasibility study.
Study population: adult patients hospitalized on the internal medicine ward and adult postoperative patients on the surgical ward.
Intervention: patients in the intervention groups will be randomized in one of the two groups. Patients in the group 1 will wear ViSi Mobile; patients in group 2 will wear the HealthPatch. Wearable devices will be worn for at least three days. Regular MEWS measurements take place at usual time points.
Main study parameters/endpoints: Evaluation with patient and care givers (primary outcome measure), MEWS calculations, time between alarm (continuous data) and next regular MEWS measurement (nurse), intervention by nurse after alarm, admission to ICU, complications, side effects of devices, STAI scores, and PCS scores will be documented.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will wear one device for at least three days. Devices can be uncomfortable by being heavy or the patches can start itching. More measurements by nurses can take place when indicated, for example after alarms. The participating patients will fill out the STAI on daily basis and the PCS on the last day of hospitalization. Both questionnaires will take a few minutes to complete. Patients could benefit from early detection of clinical deterioration and early corrective interventions or ICU admissions.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient is 18 years or older on the day the informed consent will be signed.
- Patient is hospitalized on the surgical or internal medicine ward.
- MEWS measurements are required at least three times a day.
- Patient is able to speak, read and understand the local language of the investigational site, is familiar with the procedures of the study, and agrees to participate in the study program by giving oral and written informed consent prior to screening evaluations.
Exclusion Criteria:
- Frequency of MEWS measurements is less than three times a day.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Control group
Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
|
|
|
Experimental: HealthPatch (Intervention)
Patients with HealthPatch and regular MEWS measurements
|
The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
|
|
Experimental: ViSi Mobile (Intervention)
Patients with ViSi Mobile and regular MEWS measurements
|
ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Expectations & experiences of patients
Zeitfenster: 2-3 days after informed consent
|
Interviews of 15-20 minutes with patients after 2-3 days wearing a device or control group
|
2-3 days after informed consent
|
|
Expectations & experiences of care givers
Zeitfenster: 1 year
|
Interviews with nurses of 15-20 minutes at the end of the study.
Estimated amount of 6 nurses
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
MEWS scores based on continuous data and data measured by nurses
Zeitfenster: 3 times a day, up to three days.
|
3 times a day, up to three days.
|
|
|
Amount of alarms by HealthPatch or ViSi Mobile
Zeitfenster: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Time between alarm (continuous data) and next regular MEWS measurement (nurse)
Zeitfenster: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Amount of extra MEWS measurements by nurses due to alarms
Zeitfenster: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Admission to ICU (yes/no)
Zeitfenster: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Duration of ICU hospitalization in days
Zeitfenster: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Complications caused by disease or surgical procedure
Zeitfenster: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Adverse events caused by devices
Zeitfenster: during 2-3 days when the patient wears a device
|
E.g. Itch or redness
|
during 2-3 days when the patient wears a device
|
|
Technical failures of devices (artifacts: a period longer than 1 minute the device does not measure vital parameters)
Zeitfenster: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Outcomes of the State Trait Anxiety Inventory (STAI)
Zeitfenster: Once a day during the 2-3 days the patient participantes in this study
|
Once a day during the 2-3 days the patient participantes in this study
|
|
|
Outcomes of the Pain Catastrophizing Scale (PCS)
Zeitfenster: On day 2 or 3 when patients participates in the study
|
On day 2 or 3 when patients participates in the study
|
|
|
System usability Scale
Zeitfenster: 1 year
|
1 year
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Gender
Zeitfenster: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Age
Zeitfenster: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Diagnosis
Zeitfenster: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Performed surgical procedure
Zeitfenster: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Harry van Goor, MD, PhD, FRCS, Radboud University Medical Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Adenokarzinom
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Erkrankungen des endokrinen Systems
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Neoplasmen der endokrinen Drüse
- Darmerkrankungen
- Darmerkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Erkrankungen der Bauchspeicheldrüse
- Neubildungen, duktale, lobuläre und medulläre
- Neoplasmen der Bauchspeicheldrüse
- Karzinom, duktal
- Kolorektale Neubildungen
- Karzinom, Pankreasgang
Andere Studien-ID-Nummern
- HEEL-2015-03
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .